Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrating pleural PD-1+CD8+ T cell as a complement variable into LENT score to assess patients with lung adenocarcinoma complicated with MPE.

Frontiers in immunology - 1 Jan 2026

Jiang Weizhen, Lv Leilei, Zhang Yaoxin, Qu Qiuxia, Chen Cheng

Abstract excerpt

Introduction: Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC), particularly in lung adenocarcinoma, and is associated with poor prognosis. A better understanding of the role of PD-1+CD8+ T cells in the pleural environment and their relevance to patient survival could facilitate better clinical decision-making. Methods: We performed a cohort study involving...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to CD8-Positive T-Lymphocytes

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Pleural Effusion, Malignant

Share to Programmed Cell Death 1 Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 41798922
DOI: 10.3389/fimmu.2026.1630590
PMCID: PMC12960558

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrating pleural PD-1+CD8+ T cell as a complement variable into LENT score to assess patients with lung adenocarcinoma complicated with MPE.PMID 41798922Read ↗

Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer.Semantic proximity Read ↗

Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.Semantic proximity Read ↗

Who Will Benefit Most From PD-L1 Detection and Immunotherapy in Non-small Cell Lung Cancer?Semantic proximity Read ↗

TCF-1+ PD-1+ CD8+T Cells Are Associated With The Response To PD-1 Blockade In Non-Small Cell Lung Cancer PatientsSemantic proximity Read ↗

[Correlation between the Expression of PD-L1 in Pleural Effusion of Lung Adenocarcinoma and the Clinicopathological Features and Molecular Changes].Semantic proximity Read ↗

Study on PD-L1 Expression in NSCLC Patients and Related Influencing Factors in the Real World.Semantic proximity Read ↗

A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

PD-L1 Expression in NSCLC: Clouds in a Bright SkySemantic proximity Read ↗

Phenotypic and functional characterizations of CD8+ T cell populations in malignant pleural effusion.Semantic proximity Read ↗

The expression of PD-1 ligands in the immune microenvironment was altered in TTF-1-negative lung adenocarcinomaSemantic proximity Read ↗

The Brain-Lung Immunotherapy Prognostic (BLIP) Score: A Novel Robust Tool for Prognostication in Non-Small Cell Lung Cancer Patients with Brain MetastasesSemantic proximity Read ↗

The Predictive and Prognostic Value of T- and B-cell Transcriptomic Signatures for Clinical Response to Immune Checkpoint Blockade in Pleural MesotheliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.